Paclitaxel plus bevacizumab in patients with chemoresistant relapsed small cell lung cancer as salvage treatment: A phase II multicenter study of the Hellenic Oncology Research Group

Lung Cancer

Volumn 77, Issue 1, 2012, Pages 146-150

  Mountzios, Giannis ^a   Emmanouilidis, Christos ^b   Vardakis, Nikolaos ^c   Kontopodis, Emmanouil ^c   Hatzidaki, Dora ^c   Popis, Evagelos ^d   Karachaliou, Niki ^c   Kotsakis, Athanassios ^c   Agelidou, Maria ^e   Georgoulias, Vassilis ^c  

^a Leof P Kanellopoulou   (Greece)

^b Diabalkanikon Hospital   (Greece)

^c UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^d IASO GENERAL HOSPITAL   (Greece)

^e SISMANOGLIO HOSPITAL   (Greece)

Author keywords

Bevacizumab; Chemo resistance; Paclitaxel; Salvage treatment; Second line treatment; Small cell lung cancer

Indexed keywords

BEVACIZUMAB; PACLITAXEL;

ADULT; AGED; ANEMIA; ARTICLE; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DISEASE CONTROL; DRUG EFFICACY; DRUG TOLERABILITY; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; HUMAN; HYPERTENSION; LEUKOPENIA; LUNG HEMORRHAGE; LUNG SMALL CELL CANCER; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; SALVAGE THERAPY; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG RESISTANCE, NEOPLASM; FEMALE; HEMATOLOGIC DISEASES; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL; SALVAGE THERAPY; SMALL CELL LUNG CARCINOMA; TREATMENT OUTCOME;

EID: 84861739394     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.02.002     Document Type: Article

References (24)

1. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55(2):74-108.
2. Horn L., Castellanos E.L., Johnson D.H. Update on new drugs in small cell lung cancer. Expert Opin Investig Drugs 2011, 20(4):441-445.
3. Rossi A., Maione P., Palazzolo G., Sacco P.C., Ferrara M.L., Falanga M., et al. New targeted therapies and small-cell lung cancer. Clin Lung Cancer 2008, 9(5):271-279.
4. Allen J., Jahanzeb M. Extensive-stage small-cell lung cancer: evolution of systemic therapy and future directions. Clin Lung Cancer 2008, 9(5):262-270.
5. Leighl N.B., Goss G.D., Lopez P.G., Burkes R.L., Dancey J.E., Rahim Y.H., et al. Phase II study of pegylated liposomal doxorubicin HCl (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small cell lung cancer. Lung Cancer 2006, 52(3):327-332.
6. Sandler A., Gray R., Perry M.C., Brahmer J., Schiller J.H., Dowlati A., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355(24):2542-2550.
7. Graziano S.L., Herndon J.E., Socinski M.A., Wang X., Watson D., Vokes E., et al. Phase II trial of weekly dose-dense paclitaxel in extensive-stage small cell lung cancer: cancer and leukemia group B study 39901. J Thorac Oncol 2008, 3(2):158-162.
8. Hainsworth J.D., Burris H.A., Greco F.A. Paclitaxel-based three-drug combinations for the treatment of small cell lung cancer: a review of the Sarah Cannon Cancer Center experience. Semin Oncol 2001, 28(2 (Suppl. 4)):43-47.
9. Yamamoto N., Tsurutani J., Yoshimura N., Asai G., Moriyama A., Nakagawa K. Phase II study of weekly paclitaxel for relapsed and refractory small cell lung cancer. Anticancer Res 2006, 26(1B):777-781.
10. Mori K., Kamiyama Y., Kondo T., Kano Y., Kodama T. Phase II study of weekly chemotherapy with paclitaxel and gemcitabine as second-line treatment for advanced non-small cell lung cancer after treatment with platinum-based chemotherapy. Cancer Chemother Pharmacol 2007, 60(2):189-195.
11. Shepherd F.A., Giaccone G., Seymour L., Debruyne C., Bezjak A., Hirsh V., et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. J Clin Oncol 2002, 20(22):4434-4439.
12. Grant S.C., Kris M.G., Houghton A.N., Chapman P.B. Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guerin. Clin Cancer Res 1999, 5(6):1319-1323.
13. Lucchi M., Mussi A., Fontanini G., Faviana P., Ribechini A., Angeletti C.A. Small cell lung carcinoma (SCLC): the angiogenic phenomenon. Eur J Cardiothorac Surg 2002, 21(6):1105-1110.
14. Horn L., Dahlberg S.E., Sandler A.B., Dowlati A., Moore D.F., Murren J.R., et al. Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501. J Clin Oncol 2009, 27(35):6006-6011.
15. Ready N., Dudek A.Z., Wang X., Graziano S., Green M.R., Vokes E.E. CALGB 30306 a phase II study of cisplatin (C), irinotecan (I) and bevacizumab (B) for untreated extensive stage small cell lung cancer (ES-SCLC). J Clin Oncol 2007, 25(Suppl. 18):400s. (Abstract 7563).
16. Spigel D.R., Greco F.A., Zubkus J.D., Murphy P.B., Saez R.A., Farley C., et al. Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancer. J Thorac Oncol 2009, 4(12):1555-1560.
17. Spigel D.R., Townley P.M., Waterhouse D.M., Fang L., Adiguzel I., Huang J.E., et al. Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial. J Clin Oncol 2011, 29(16):2215-2222.
18. Jalal S., Bedano P., Einhorn L., Bhatia S., Ansari R., Bechar N., et al. Paclitaxel plus bevacizumab in patients with chemosensitive relapsed small cell lung cancer: a safety, feasibility, and efficacy study from the Hoosier Oncology Group. J Thorac Oncol 2010, 5(12):2008-2011.
19. Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45(January (2)):228-247.
20. Vokes E., Herbst R., Sandler A. Angiogenesis inhibition in the treatment of lung cancer. Clin Adv Hematol Oncol 2006, 4(November 11 (Suppl. 23)):1-10.
21. Zubkus J.D., Spigel D.R., Greco F.R., Yardley A., Burris H.A., Vazquez E., et al. Phase II trial of irinotecan, carboplatin, and bevacizumab in patients with limited-stage small cell lung cancer. J Clin Oncol 2007, 25(Suppl. 18):400s. (Abstract 18133).
22. von Pawel J., Schiller J.H., Shepherd F.A., Fields S.Z., Kleisbauer J.P., Chrysson N.G., et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999, 17(2):658-667.
23. Geiger-Gritsch S., Stollenwerk B., Miksad R., Guba B., Wild C., Siebert U. Safety of bevacizumab in patients with advanced cancer: a meta-analysis of randomized controlled trials. Oncologist 2010, 15(11):1179-1191.
24. Spigel D.R., Hainsworth J.D., Yardley D.A., Raefsky E., Patton J., Peacock N., et al. Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab. J Clin Oncol 2010, 28(1):43-48.